# Heungkuk Asset Management

> Heungkuk Asset Management is a VC fund in Seoul backing Biotechnology and Therapeutics. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 17
- Last investment: Jun 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/heungkuk-asset-management-co-ltd/
- Website: http://www.heungkuksec.co.kr/

Heungkuk Asset Management is a financial services firm that specializes in stocks, fixed income, mixed assets, and hedge funds, and others.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 41% |
| Therapeutics | 4 | 24% |
| Pharmaceutical | 3 | 18% |
| Health Care | 2 | 12% |
| Manufacturing | 2 | 12% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 24% |
| Series A | 3 | 18% |
| Series C | 2 | 12% |
| Seed | 1 | 6% |
| Private Equity | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 10 | 59% |
| United States | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nventric | Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M | Venture - Series Unknown | Jun 10, 2026 |  |
| Novacos | Novacos develops cosmetic and skincare products through OEM and ODM manufacturing. The company handles formulation development, product production, packaging, quality control, and private-label cosmetics services. | $1.4M | Seed | Oct 01, 2025 |  |
| CURAUM | CURAUM is a specialist in oral care and sleep-related health care products. | $14.6M | Series C | May 25, 2025 |  |
| Global Technologies | Global Technologies specializes in developing core sensors and advanced sensor systems. Leveraging proprietary semiconductor and software technology, they provide high-performance solutions for environmental sensing and industrial applications. Based in Korea, the company focuses on innovation in sensor hardware to enable smarter data collectionand automation across various global markets. | $9.4M | Series A | Jul 04, 2024 |  |
| Avelos Therapeutics | Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $12.4M | Series B | May 02, 2024 |  |
| DewCell | Dewcell Biotherapeutics develops synthetic platelets using biomimetic technology. The company's system secures stem cell differentiation technology into megakaryocytes that generate platelets and mass-produces artificial platelets. | $6.6M | Series B | Apr 29, 2024 |  |
| Artblood | ArtBlood is a biotechnology company that offers cell-based artificial blood production and regenerative medicine. The company develops innovative in vitro red blood cell (RBC) production technologies using stem cell–based platforms. | $4.8M | Series A | Apr 09, 2024 |  |
| BioResearchAI | BioResearchAI is a research platform that provides bio-healthcare field database with AI technology for researchers. The company provides virtual wardrobe management, outfit recommendations, and digital fashion experiences to improve online and in-store shopping experiences. | $1.5M | Seed | Apr 02, 2024 |  |
| Nventric | Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $10.5M | Series B | Feb 06, 2024 |  |
| DAAN Biotherapeutics | DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $17.2M | Series A | Jan 25, 2024 |  |

10 of 17 investments shown.

## Co-investors
- [Shinhan Capital](https://shizune.co/investors/profile/shinhan-capital) — VC Fund, 8 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 4 deals together
- [HB Investment](https://shizune.co/investors/profile/hb-investment) — VC Fund, 3 deals together
- [Quad Asset Management](https://shizune.co/investors/profile/quad-asset-management-2471) — VC Fund, 3 deals together
- [Timepolio Asset Management](https://shizune.co/investors/profile/timepolio-asset-management) — VC Fund, 3 deals together
- [Aju IB Investment](https://shizune.co/investors/profile/aju-ib-investment) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Heungkuk Asset Management invest in?

Heungkuk Asset Management invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Heungkuk Asset Management last invest?

The most recent investment recorded for Heungkuk Asset Management closed in Jun 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co